Plus Therapeutics Soars 12.93% on FDA Nod

On March 27, 2025, Plus Therapeutics' stock surged by 12.93% in pre-market trading, marking a significant rise for the biotechnology company.

Plus Therapeutics' stock experienced a notable surge following the FDA's conditional acceptance of the company's new proprietary name, Reyobiq, for its lead drug. This development has generated considerable optimism among investors, driving the stock's pre-market rally.

Additionally, Plus Therapeutics is scheduled to release its quarterly earnings data after the market close on March 27, 2025. This upcoming earnings report is anticipated to provide further insights into the company's financial performance and strategic direction, potentially influencing investor sentiment and stock price movements.